SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer
John T. Phoenix, Audris Budreika, Devin A. Schmeck, Raymond J. Kostlan, Marina G. Ferrari, Kristen S. Young, Charles S. Rogers, Carleen D. Deegan, Marcus W. Bienko, Hannah E. Bergom, Ella Boytim, Ryan M. Brown, Julia A. Walewicz, Shreya K. Bhagi, Leigh Ellis, , Steven Kregel
This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.
bioRxiv · Jul 18, 2025 · PreprintCancer Biology